ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1859

Clonal Relationships Between Tph and Tfh Cells in Patients with SLE and in Murine Lupus
Abstract Number: 0346

Clonally Expanded and Total B Cells in Patients with Idiopathic Inflammatory Myopathies Show Skewed B Cell Subset Distribution and Reduced Somatic Hypermutation Relative to Healthy Controls
Abstract Number: 0430

Clues from Early Gestational Mean Arterial Pressure in Predicting Preeclampsia Risk in Systemic Lupus Erythematosus (SLE)
Abstract Number: 0484

Cluster Analysis Based on Joint Characteristics: A Study of Joint Involvement Profiles in Early Rheumatoid Arthritis (ERA) Patients in China
Abstract Number: 1704

Cluster Analysis of Peripheral Blood Mononuclear Cell Subpopulations Using Deep Immunophenotyping, Multiplex Serum Cytokines and Small Lipid Mediators at the Very Early Stages of Steroid Treatment in Polymyalgia Rheumatica and Giant Cell Arteritis
Abstract Number: 2442

Clustering Algorithm as an Exploratory Analysis of Different Clinical Phenotypes in Systemic Sclerosis. Data from the PRECISESADS Study
Abstract Number: 2060

Clustering Analysis of Immune Cell Subtypes and Clinical Phenotypes in Idiopathic Inflammatory Myopathy
Abstract Number: 1723

Clustering Analysis with Unsupervised Machine Learning Process to Phenotype the Cardiovascular Risk of Patients with Rheumatoid Arthritis Beyond the 10-year Prediction Algorithm
Abstract Number: 1858

Co-modification of Citrullinated Proteins with Malondialdehyde-Acetaldehyde Leads to Amplified T Cell Responses and Increased Disease-specific Autoantibody Concentrations
Abstract Number: 1618

Co-occurrence of Giant Cell Arteritis and Polymyalgia Rheumatica: Insights from a Retrospective Analysis
Abstract Number: 0512

Co-stimulatory Blockade Causes Targeted Quantitative and Clonotypic Contractions in Extrafollicular B-cell Subsets in Seropositive RA Patients
Abstract Number: 0568

Coexistence of Raynaud’s Phenomenon, Morphea or Scleroderma in Spondyloarthritis Patients: Insights from a Retrospective Cohort Study Highlighting a Unique Phenotype
Abstract Number: 0624

Coexisting Tubulointerstitial Inflammation and Damage Is a Risk Factor for Chronic Kidney Disease in Patients with Lupus Nephritis
Abstract Number: 1506

Cognitive Impairment Prevalence and Most Affected Domains in Patients with SLE by the ACR Comprehensive Neuropsychological Battery
Abstract Number: 1389

Cohort Study on Drug Survival and Tolerability of Adalimumab Biosimilar Transitioning: Pharmaceutical Properties Do Matter

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].